Supercharge Your Innovation With Domain-Expert AI Agents!

Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders

A composition and drug technology, applied in the direction of drug combination, anti-inflammatory agent, pharmaceutical formula, etc., can solve the problem of small effect

Inactive Publication Date: 2010-06-16
BIOCELL LAB
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In detail, since conventional therapy has little effect on large infarcts implicated in cardiogenic shock, there is a need for new drugs that prevent the destruction of cardiomyocytes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders
  • Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders
  • Compound, composition and method for the treatment of inflammatory and inflammatory-related disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0103] Embodiment 1. The method for preparing yeast RNA

Embodiment 11

[0104] Example 1.1 Production of Yeast RNA

[0105]Preparation of RNA-D from S. cerevisiae and RNA-P, RNA-PN and RNA-F from Candida utilis. Yeast RNA extraction was carried out at 100-110°C with 10-12% sodium chloride solution. The RNA solution was isolated from the yeast pellet, cooled to 0 °C and acidified to pH 1-2 with HCl. Precipitated RNA was rinsed with alcohol, dried and dissolved in water. The solution was adjusted to pH 8.0-8.2 with sodium hydroxide. Place at 37-40°C for about 1 hour after adding trypsin. Heat to inactivate the enzyme, then filter the solution. RNA was precipitated from cold alcohol, acidified to pH 1-2 with hydrochloric acid, and dried. RNA-F was prepared in this way. Further, the precipitate was filtered, rinsed with alcohol, and then dissolved in water adjusted to pH 6.2-6.5 by adding sodium hydroxide. RNA-PN was precipitated by ethanol. The precipitate was filtered and dried. RNA-P was derived from RNA-F by repurification from protein by...

Embodiment 12

[0110] Example 1.2. No toxicity

[0111] We confirmed the non-toxicity of yeast RNA-P and RNA-D. Intraperitoneal administration of single or multiple doses of yeast RNA in biologically active amounts (250-500 mg / kg body weight) did not result in substantial changes in the number of peripheral lymphocytes in mice. These changes would be characteristic indicators of endotoxin.

[0112] Similar results were obtained with intravenous introduction of nucleic acids. We measured changes in the amount of peripheral leukocytes 1-3 hours after intravenous injection of 100 mg of yeast RNA-P or RNA-D solution in rabbits. An intravenous injection of 0.85% NaCl solution was used as a non-toxicity standard. The experimental results proved that, similar to the standard, the injection of yeast RNA-P or RNA-D did not induce changes in the number of white blood cells within 3 hours of introduction. In animals administered 0.85% NaCl solution, the amount of leukocytes was equal to 13000±980, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention concerns a compound consisting of RNA, in particular RNA extracted from yeast, a pharmaceutical composition comprising such RNA and a method for the treatment of inflammatory andinflammatory-related disorders comprising administering to a patient in need of such treatment a pharmaceutical composition comprising an amount effective to ameliorate the symptoms of inflammation or inflammatory-related disorder of ribonucleic acid and a pharmaceutically acceptable vehicle, carrier, or diluent. The exogenous yeast RNA used in the present invention has a pronounced membrane-stabilizing action in a wide range of concentrations. At the same time, yeast RNA normalizes metabolism of arachidonic acid and levels of its key metabolites, thromboxane and leukotriene. Its anti-inflammatory action is accompanied by normalization of the activity of NO-synthetase and anti-oxidant activity.

Description

field of invention [0001] The present invention relates to compounds and pharmaceutical compositions for the treatment of inflammation and diseases accompanied by inflammatory processes, especially those affecting cell membranes. The invention also relates to methods of treatment for alleviating or preventing symptoms of an inflammatory process. Background of the invention [0002] inflammatory process [0003] Inflammation is often accompanied by changes in arachidonic acid metabolism, nitric oxide metabolism, and free radical production. Anti-inflammatory non-steroidal drugs (NSAIDS) such as aspirin block some links of the inflammatory process, but these drugs do not stabilize damaged cell membranes, which makes their effect on the inflammatory process limited and insufficient. [0004] Inflammation is a local reaction of living tissue due to injury, which can be caused by various endogenous and exogenous factors. Exogenous factors include physical, chemical and biologi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/11A61K31/7105
CPCA61K31/7105A61P29/00A61P37/00A61P7/00
Inventor 泽诺维伊·特卡丘克
Owner BIOCELL LAB
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com